{
    "title": "106_hr4705",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Public Investment Recovery Act of \n2000''.\n\nSEC. 2. RECOUPMENT REQUIREMENT.\n\n    Each transaction entered into by an agency of the Federal \nGovernment under which Federal support is provided for research and \ndevelopment which leads or may lead to the production and sale of a \npharmaceutical, biologic, or genetic product shall include provisions \nrequiring that payments described in section 4 shall be paid annually \nto the Federal agency for deposit in the Public Investment Recovery \nTrust Fund established under section 6.\n\nSEC. 3. PUBLIC INVESTMENT RECOVERY BOARD.\n\n    (a) Establishment.--There shall be established a Public Investment \nRecovery Board, consisting of--\n            (1) a chairperson, who shall be an employee of the National \n        Science Foundation appointed by the Director of the National \n        Science Foundation;\n            (2) a representative of the Internal Revenue Service;\n            (3) a representative of the Food and Drug Administration;\n            (4) a representative of the Department of the Treasury;\n            (5) a representative of the National Institutes of Health;\n            (6) a representative of the Office of Science and \n        Technology Policy; and\n            (7) 3 nonvoting members appointed under subsection (b)(1).\n    (b) Nonvoting Members.--\n            (1) Appointment.--The President shall appoint 3 nonvoting \n        members to the Board from among appropriate nonprofit \n        scientific and medical societies, such as the American \n        Association of Medical Colleges, the American Pharmaceutical \n        Association, and the Biotechnology Industry Organization. The \n        President shall seek to ensure broad representation of \n        appropriate points of view in making appointments under this \n        paragraph.\n            (2) Terms.--Members appointed under paragraph (1) shall \n        serve 3-year terms, except that of the initial appointments 1 \n        member shall be appointed to a 1-year term and 1 member shall \n        be appointed to a 2-year term.\n            (3) Compensation.--Members appointed under this subsection \n        shall receive no compensation for service on the Board.\n    (c) Functions.--The Board shall--\n            (1) determine, for purposes of section 4(a), the total \n        amount of profits that have been received with respect to a \n        pharmaceutical, biologic, or genetic product, including profits \n        received by a person not a party to the transaction with the \n        Federal agency; and\n            (2) make calculations under section 5 of the proportion of \n        Federal support for research and development which lead to the \n        production and sale of a pharmaceutical, biologic, or genetic \n        product.\n    (d) Administrative Support.--The National Science Foundation shall \nprovide necessary administrative support for the Board and its staff.\n\nSEC. 4. AMOUNT OF PAYMENT REQUIRED.\n\n    (a) General Rule.--Except as provided in subsection (b), the amount \nthat shall be required to be paid under section 2 to a Federal agency \nshall be equal to the total amount of profits determined by the Board \nunder section 3(c)(1) to have been received with respect to the \npharmaceutical, biologic, or genetic product up to the time of payment, \nmultiplied by the percentage calculated by the Board under section 5.\n    (b) Limitation.--No annual payment shall be required under this Act \nthat exceeds 20 percent of the profits determined by the Board to have \nbeen received during the year for which the payment is made.\n    (c) Expiration of Requirement.--The requirement to make payments \nunder this Act shall expire on the expiration of the initial patent \nissued for the pharmaceutical, biologic, or genetic product.\n\nSEC. 5. CALCULATION OF PERCENTAGE.\n\n    The Board shall calculate, for each pharmaceutical, biologic, or \ngenetic product sold for which Federal support was provided through a \ntransaction described in section 2, the percentage that Federal support \nrepresents of the total research and development that supported the \nproduction and sale of the product.\n\nSEC. 6. PUBLIC INVESTMENT RECOVERY TRUST FUND.\n\n    (a) Establishment.--The Secretary of the Treasury shall establish \nan account in the Treasury to be known as the ``Public Investment \nRecovery Trust Fund'', into which shall be deposited all payments \nreceived by the Federal Government pursuant to this Act.\n    (b) Purposes.--Amounts in the Trust Fund may be used, to the extent \nprovided in advance in appropriations Acts, for the following purposes:\n            (1) Not more than 2 percent may be used by the Food and \n        Drug Administration or the National Institutes of Health to \n        support research on the comparative efficiency and \n        effectiveness of pharmaceutical, biologic, or genetic products \n        and the reporting thereof.\n            (2) Not more than--\n                    (A) 20 percent, in each of the first 5 fiscal years \n                after the date of the enactment of this Act; and\n                    (B) 3 percent, in subsequent fiscal years,\n        may be used to help pay the administrative expenses of carrying \n        out this Act.\n            (3) Not more than 20 percent may be used by the National \n        Institutes of Health to support pharmaceutical, biologic, or \n        genetic research and development, unless no Medicare \n        prescription drug benefit has been enacted by the Congress, in \n        which case the remainder of the funds in the Trust Fund may be \n        used for the purpose under this paragraph.\n            (4) If a Medicare prescription drug benefit has been \n        enacted by the Congress, the remainder of the funds in the \n        Trust Fund shall be used for financing such prescription drug \n        benefit, except that any amounts available in the Trust Fund in \n        excess of amounts required for financing such prescription drug \n        benefit may be used for the purpose stated in paragraph (3).\n\nSEC. 7. DEFINITIONS.\n\n    In this Act--\n            (1) the term ``Board'' means the Public Investment Recovery \n        Board established under section 3;\n            (2) the term ``Federal support'' includes direct Federal \n        research and development funding support, the cost of research \n        and development conducted by the Federal Government and used in \n        support of the production and sale of a product, and the \n        relevant proportion of Federal funding support for any \n        nonprofit organization conducting research and development that \n        is used in support of the production and sale of a product; and\n            (3) the term ``pharmaceutical, biologic, or genetic \n        product'' has the meaning given the term ``covered outpatient \n        drug'' under section 1927(k)(2) of the Social Security Act (42 \n        U.S.C. 1396r-8(k)(2))."
}